Search

Your search keyword '"Abudurexiti, Mierxiati"' showing total 18 results
Start Over Author "Abudurexiti, Mierxiati" Publication Year Range Last 10 years
18 results on '"Abudurexiti, Mierxiati"'

3. Integrated analysis of intratumoral biomarker and tumor-associated macrophage to improve the prognosis prediction in cancer patients

Author

Ming-Da Wang, Hao Xiang, Tian-Yu Hong, Abudurexiti Mierxiati, Fei-Hu Yan, Ling Zhang, and Chao Wang

Subjects
Hepatocellular carcinoma, Tumor-associated Macrophage, HBx, CD68, Prognosis, Predictive accuracy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The lack of effective and accurate predictive indicators remains a major bottleneck for the improvement of the prognosis of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Hepatitis B virus X (HBx) has been widely suggested as a critical pathogenic protein for HBV-driven liver carcinogenesis, while tumor-associated macrophage (TAM) infiltration is also closely related to the tumorigenesis and progression of HCC. However, few studies have determined whether combining HBx expression with TAM populations could increase the accuracy of prognostic prediction for HBV-related HCC. Methods The study cohort enrolling 251 patients with HBV-related HCC was randomly split into a training and a validation group (ratio 1:1). The expression levels of HBx and TAM marker CD68 in HCC samples were detected by immunohistochemistry. Kaplan–Meier curves, Cox regression and Harrell’s concordance index (C-index) analysis were conducted to evaluate the prognostic significance of these indicators alone or in combination. Results The expression level of HBx was strongly correlated with CD68+ TAM infiltration in HCC tissues. Elevated HBx or CD68 expression indicated poorer overall survival (OS) and progression-free survival (PFS) after hepatectomy, and both of them were independent risk factors for postoperative survival. Meanwhile, patients with both high HBx and CD68 levels had worst clinical outcomes. Moreover, integrating HBx and CD68 expression with clinical indicators (tumor size and micro-vascular invasion) showed the best prognostic potential with highest C-index value for survival predictivity, and this proposed model also performed better than several conventional classifications of HCC. Conclusion Combining the expression of intratumoral HBx, CD68+ TAM population and clinical variables could enable better prognostication for HBV-related HCC after hepatectomy, thus providing novel insights into developing more effective clinical prediction model based on both molecular phenotypes and tumor-immune microenvironment.

Published
2023
Full Text
View/download PDF

4. Integration Analysis of Single‐Cell Multi‐Omics Reveals Prostate Cancer Heterogeneity

Author

Bian, Xiaojie, primary, Wang, Wenfeng, additional, Abudurexiti, Mierxiati, additional, Zhang, Xingming, additional, Ma, Weiwei, additional, Shi, Guohai, additional, Du, Leilei, additional, Xu, Midie, additional, Wang, Xin, additional, Tan, Cong, additional, Sun, Hui, additional, He, Xiadi, additional, Zhang, Chenyue, additional, Zhu, Yao, additional, Zhang, Min, additional, Ye, Dingwei, additional, and Wang, Jianhua, additional

Published
2024
Full Text
View/download PDF

8. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers

Author

Wang, Jun, primary, Xu, Wenhao, additional, Wang, Beihe, additional, Lin, Guowen, additional, Wei, Yu, additional, Abudurexiti, Mierxiati, additional, Zhu, Wenkai, additional, Liu, Chang, additional, Qin, Xiaojian, additional, Dai, Bo, additional, Wan, Fangning, additional, Zhang, Hailiang, additional, Zhu, Yao, additional, and Ye, Dingwei, additional

Published
2020
Full Text
View/download PDF

9. Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer

Author

Abudurexiti, Mierxiati, primary, Zhu, Wenkai, additional, Wang, Yuchen, additional, Wang, Jun, additional, Xu, Wenhao, additional, Huang, Yongqiang, additional, Zhu, Yao, additional, Shi, Guohai, additional, Zhang, Hailiang, additional, Zhu, Yiping, additional, Shen, Yijun, additional, Dai, Bo, additional, Wan, Fangning, additional, Lin, Guowen, additional, and Ye, Dingwei, additional

Published
2020
Full Text
View/download PDF

12. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

Author

Yongqiang Huang, Yao Zhu, Wenhao Xu, Jun Wang, Xiaojian Qin, Abudurexiti Mierxiati, Stephen J. Freedland, Yu Wei, Dingwei Ye, Guowen Lin, and Bo Dai

Subjects
0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Adolescent, Urology, Adenocarcinoma, GPI-Linked Proteins, Neuroendocrine differentiation, Cohort Studies, 03 medical and health sciences, Prostate cancer, Young Adult, 0302 clinical medicine, Antigens, Neoplasm, Internal medicine, Epidemiology, medicine, Humans, Aged, Proportional hazards model, business.industry, Hazard ratio, Bone metastasis, Prostatic Neoplasms, Cell Differentiation, Middle Aged, medicine.disease, Prognosis, Confidence interval, United States, Carcinoma, Neuroendocrine, Neoplasm Proteins, 030104 developmental biology, 030220 oncology & carcinogenesis, business, SEER Program
Abstract

Background The rarities of primary neuroendocrine prostate cancer (NEPC) and primary adenocarcinoma with neuroendocrine differentiation (NE differentiation) mean that their clinical characteristics have not been fully elucidated. Materials and methods A total of 449 patients with NEPC, including 352 cases of pure NEPC and 97 cases of NE differentiation, together with 408 629 cases of prostate adenocarcinoma at diagnosis were retrieved from the Surveillance, Epidemiology, and End Results program (2010-2015). Clinical parameters and prognoses were compared between patients with different histological types of NEPC using the χ2 test and Kaplan-Meier analysis, respectively. The prognostic value of prostate-specific antigen (PSA) in NEPC and adenocarcinoma was evaluated using Cox regression and the Kaplan-Meier method. Results Pure NEPC had higher rates of visceral metastases (brain, lung, and liver: 4.58%, 26.72%, and 36.64%, respectively) but a lower rate of bone metastasis (65.65%) compared with NE differentiation and prostate adenocarcinoma. Moreover, patients diagnosed with pure NEPC had a poorer outcome (median survival time: 10 months) compared with patients with NE differentiation (26 months) and prostate adenocarcinoma (median survival time not reached). Using PSA 4.1 to 10 ng/mL as the reference, the adjusted hazard ratios (HRs) for PSA lower than or equal to 4.0 ng/mL were 2.24 (95% confidence interval [CI]: 1.11-4.55, P = .025) in the NE differentiation group and 1.57 (95% CI: 1.11-2.23, P = .011) in the pure NEPC group. Conclusions Patients with NE differentiation had different clinical characteristics and a better prognosis than patients with pure NEPC. In addition, low-serum PSA levels were associated with a poorer prognosis in patients with either NEPC or NE differentiation.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results